Table 1. Demographics of the trial population.
| ALL | Symptomatic | Asymptomatic | Healthy control |
|||
|---|---|---|---|---|---|---|
| Diagnosed with active TB* | Non-TB | PTB contact | ||||
| Trial participants | 1190 | 75 | 928 | 87 | 100 | |
| Age (years) | ||||||
| Median (range) | 17 (0–65) | 32 (0–62) | 25 (0–65) | 2 (0–4) | 8 (5–11) | |
| <5 | 236 (20) | 2 (3) | 147 (16) | 87 (100) | 0 (0) | |
| 5–17 | 366 (31) | 13 (17) | 253 (27) | 0 (0) | 100 (100) | |
| ≥18 | 588 (49) | 60 (80) | 528 (57) | 0 (0) | 0 (0) | |
| Sex | ||||||
| Male | 589 (49) | 40 (53) | 465 (50) | 43 (49) | 53 (53) | |
| Female | 601 (51) | 35 (47) | 463 (50) | 44 (51) | 47 (47) | |
| Ethnicity | ||||||
| African descent | 909 (76) | 55 (73) | 806 (87) | 48 (55) | 0 (0) | |
| Other | 291 (24) | 20 (27) | 122 (13) | 39 (45) | 100 (100) | |
| BCG status | ||||||
| Vaccinated | 882 (74) | 45 (60) | 655 (71) | 86 (99) | 96 (96) | |
| Not vaccinated | 264 (22) | 25 (33) | 234 (25) | 1 (1) | 4 (4) | |
| Unknown | 44 (4) | 5 (7) | 39 (4) | 0 (0) | 0 (0) | |
| HIV | ||||||
| Uninfected | 730 (61) | 40 (53) | 566 (61) | 24 (28) | 100 (100) | |
| Unknown | 161 (14) | 1 (1) | 97 (10) | 63 (72) | 0 (0) | |
| Infected | 299 (25) | 34 (45) | 265 (29) | 0 (0) | 0 (0) | |
| CD4 (HIV-infected) † | ||||||
| <100 | 40 (14) | 12 (35) | 28 (11) | N.A. | N.A. | |
| ≥100 | 246 (86) | 22 (65) | 224 (89) | N.A. | N.A. | |
Data are presented as n, median (range) or n (%).
*Microbiologically confirmed during the trial after skin testing.
†13 missing CD4 count.